The analysis made in this report helps in understanding the strategies adopted by various companies for gaining market share in Kidney Fibrosis Treatment Market
Portland, OR -- (SBWIRE) -- 07/27/2017 -- Fibrosis is the body process in which excess fibrous connective tissue is formatted in the organ or tissue in repetitive way. Fibrosis may be resulted by specific injuries or diseases. Kidney fibrosis is the common pathway for the chronic kidney disease (CKD) or end-stage kidney diseases (ESRD). Kidney fibrosis is caused by the excessive formation of the extracellular matrix, which is the common phenomenon caused by each type of CKD. Currently, kidney fibrosis market is facing lucrative growth owing to rising incidences of CKDs and renal fibrosis. Increasing patients' base may promote the future growth of this market.
Get full summary of the Report:https://www.alliedmarketresearch.com/kidney-fibrosis-treatment-market
The Kidney fibrosis market is segmented based on therapeutics, location of testing, and geography. Based on the type of treatment, the market is further segmented into Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Pirfenidone, Renin Inhibitors and Vasopeptidase Inhibitors. Based on the location of testing, the market is segmented into hospital, clinic, and home treatments. Currently, hospitals perform a majority of tests and would continue to hold a larger market share, both in terms of volume and revenue of the treatments. Geographically, the global Kidney Fibrosis Treatment Market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
Some of the key players working in the kidney fibrosis treatment market include Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., Galectin Therapeutics, La Jolla Pharmaceutical Company, InterMune Inc., ProMetic Life-Sciences Inc., Genzyme Corporation, BioLine Rx Ltd among others.
Get sample of the Report:https://www.alliedmarketresearch.com/request-toc-and-sample/614
KEY MARKET SEGMENTS
The market is segmented based on the type of treatments, location of testing, and by the geography.
KIDNEY FIBROSIS TREATMENT MARKET BY THERAPEUTICS
-Angiotensin II receptor blockers (ARBs)
-Angiotensin Converting Enzyme (ACE) inhibitors
-Pirfenidone
-Renin Inhibitors
-Vasopeptidase Inhibitors
KIDNEY FIBROSIS TREATMENT MARKET BY LOCATION OF THERAPEUTICS
-Hospital testing
-Commercial/private hospitals
-Public health hospitals
-Clinics
-Home Treatment
KIDNEY FIBROSIS TREATMENT MARKET BY GEOGRAPHY-
-North America
-Europe
-Asia-Pacific
-LAMEA